国邦医药(605507) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,338,703,044.52, representing a decrease of 5.07% compared to the same period last year[5]. - The net profit attributable to shareholders of the listed company was CNY 198,731,128.32, an increase of 2.11% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 192,939,576.15, reflecting a slight increase of 0.48%[5]. - The net profit for Q1 2024 was CNY 198,578,686.05, an increase of 1.55% compared to CNY 194,971,355.47 in Q1 2023[18]. - Basic and diluted earnings per share for Q1 2024 were both CNY 0.36, up from CNY 0.35 in Q1 2023[19]. Cash Flow - The net cash flow from operating activities was negative at CNY -79,114,596.07, a significant decrease of 137.61% compared to the previous year[5]. - Cash flow from operating activities showed a net outflow of CNY 79,114,596.07, a significant decrease from a net inflow of CNY 210,380,795.68 in the same period last year[21]. - Cash inflow from operating activities totaled CNY 1,058,961,855.16, slightly up from CNY 1,056,638,577.97 in Q1 2023[20]. - Cash outflow from operating activities increased to CNY 1,138,076,451.23, compared to CNY 846,257,782.29 in Q1 2023[21]. - The total cash and cash equivalents at the end of Q1 2024 were CNY 1,706,747,877.14, down from CNY 1,934,456,200.04 at the end of Q1 2023[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,400,762,610.74, showing a slight increase of 0.38% from the end of the previous year[6]. - Total assets as of March 31, 2024, amounted to CNY 10,400,762,610.74, compared to CNY 10,361,635,348.92 at the end of 2023[14]. - Total liabilities decreased to CNY 2,792,051,051.34 from CNY 2,924,446,559.57, a reduction of 4.52%[14]. - Shareholders' equity increased to CNY 7,608,711,559.40 from CNY 7,437,188,789.35, reflecting a growth of 2.30%[14]. Operating Costs and Profit - Total operating costs for Q1 2024 were CNY 1,100,097,238.84, down 6.73% from CNY 1,179,880,936.98 in Q1 2023[16]. - Operating profit for Q1 2024 increased to CNY 236,105,375.84, compared to CNY 230,550,561.32 in Q1 2023, reflecting a growth of 2.41%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,972[9]. Research and Development - Research and development expenses for Q1 2024 were CNY 37,654,589.30, down from CNY 46,857,324.22 in Q1 2023, a decrease of 19.6%[16]. Non-Recurring Gains - The company reported non-recurring gains of CNY 5,791,552.17 for the period, primarily from government subsidies and other income[7]. Borrowings and Tax Refunds - The company received CNY 203,000,000.00 in borrowings during Q1 2024, an increase from CNY 93,000,000.00 in Q1 2023[21]. - The company reported a decrease in tax refunds received, totaling CNY 46,644,459.61 in Q1 2024, down from CNY 67,497,670.64 in Q1 2023[20].